Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Research

| More

Metropolis Healthcare - Strong performance aided by COVID-19 tests - ICICI Securities

Posted On: 2020-11-18 01:30:07


Metropolis Healthcare (Metropolis) reported Q2FY21 performance better than estimates aided by COVID-19 tests and improved operational efficiency. Non-COVID volumes (no. of patients) dropped 23.3% but its average realisation (revenue/patient) improved 10.4% YoY. Overall, revenue grew 29.1% YoY to Rs2.9bn (I-Sec: Rs2.8bn). EBITDA margin improved 350bps to 31.5% led by higher revenue and improved operational efficiency. COVID-19 related RT-PCR tests contributed ~35% of total sales. The non-COVID revenue saw strong recovery and grew ~6% in Sep'20. We expect growth in non-COVID business to continue to improve in coming quarters. Aggressive network expansion with B2C focus and expectation of faster shift of market to organised players would help Metropolis to continue strong growth momentum. Retain ADD.

- Strong revenue growth: Metropolis witnessed revenue growth of 29.1% while non-COVID tests witnessed a decline of 15.4% YoY during Q2FY21 due to impact of lockdown in Jul-Aug. The business recovered well in Sep'20 and grew ~6% YoY. COVID-19 tests contributed ~35% to total sales and management expects revenue from COVID-19 tests to continue to support the growth in near term, however its contribution would slowly taper down. Realisation per patient (ex-COVID) improved 10.4% to Rs926. We believe non-COVID volumes would improve in the coming quarters and expect double digit growth Q3FY21 onwards. The anti-body and anti-gen tests contributed ~3.5% of total sales. The tests per patient metrics remained steady at 1.95x.

- Higher revenue and operational efficiency helped in margin beat: Metropolis reported an EBITDA margin of 31.5%, an increase of 350bps YoY primarily because of higher revenue growth and improved operational efficiency. The company had undertaken cost rationalisation program which helped in reducing fixed and variable costs. Part of these savings would be rolled back as business has reverted to pre-COVID levels. We expect EBITDA margin to improve 260bps over FY20-FY23E to reach 29.8% in FY23E.

- Outlook: We expect Metropolis to register revenue, EBITDA and PAT growth at CAGRs of 15.1%, 18.7% and 21.3%, respectively, over FY20-FY23E. RoE and RoCE would remain strong at ~33% each in FY23E whereas RoIC would move to 68.8%. We are positive on the long-term outlook given strong brand franchise with sustainable growth, healthy FCF and potential shift of unorganised market to organised players.

- Valuation: We raise our revenue/EBITDA estimates by 0-1/2-6% to factor in higher revenue from COVID-19 tests and cost savings. We maintain ADD rating on the stock with a revised DCF-based target price of Rs2,100/share (earlier: Rs2,058/share) implying 40.8xFY23E EPS and 26.0xFY23E EV/EBITDA. Key downside risks: Higher-than-expected competition and pricing pressures.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com



Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Vardhman Special Steel - Q2FY21 Company Update - ICICI Direct

Initiating Coverage - Advanced Enzyme Technologies - ICICI Direct

L&T - Secures Large Contract - Nov 25, 2020 - Angel Broking

Alembic Pharmaceuticals - Tentative Approval for JV - Angel Broking

Drug launch by Lupin - Tacrolimus Capsules - Angel Broking

Gujarat Gas - Nov 25, 2020 - Angel Broking

Metropolis Healthcare - Nov 25, 2020 - Angel Broking

NTPC - Showcase of strength & competitiveness - ICICI Securities

Telecom - Market Share TRACKER - Bharti is narrowing the gap on incremental market share vs RJio - ICICI Securities

Cochin Shipyard - Q2FY21 Result Update - ICICI Direct

Engineers India - Q2FY21 Result Update - ICICI Direct

Rupee - Nov 24, 2020 - Reliance Securities

FMCG Sector Update - Recovery unlocked; lower growth divergence - HDFC Securities

Engineers India - Consultancy segment outperformance - ICICI Securities

Engineers India - Q2 FY21 Result Update - YES SECURITIES

Motherson Sumi Systems - Company Update - Virtual Investor Conference - ICICI Direct

Mutual Fund Review - November, 2020 - ICICI Direct

Sadbhav Engineering - Q2FY21 Company Update - ICICI Direct

IRB Infrastructure - Q2FY21 Company Update - ICICI Direct

Vodafone Idea fund raising - Angel Broking

Rupee - Nov 23, 2020 - Reliance Securities

Crude Oil - Nov 23, 2020 - Reliance Securities

Q2FY21 Bank Result Quick Review - Angel Broking

Banks & NBFC's Sector Update Report - Yet another watershed moment? - HDFC Securities

Galaxy Surfactants - EBITDA/kg has an upside risk - ICICI Securities

Diagnostics - COVID-19 tests continue to trend higher - ICICI Securities

Banking & Financial Services - Sector Update - Nov 22, 2020 - ICICI Direct

Dalmia Bharat Sugar - Q2FY21 Company Update - ICICI Direct

Balkrishna Industries - Industry export growth momentum continues - ICICI Securities

Covid Recovery Pulse - Festive positivity continues in auto retails, E-way bill generation improves... - ICICI Direct

Quant Pick - Exide Industries - ICICI Direct

Shankara Building Products - Q2FY21 Company Update - ICICI Direct

Triveni Engineering - Q2FY21 Company Update - ICICI Direct

Initiating Coverage on Sudarshan Chemical - Leaping into the league of giants - HDFC Securities

Earnings Wrap Q2FY21: Earnings outperform, post Covid recovery picks up steam - ICICI Direct

Vodafone Idea Positive development beneficial for IDFC first bank - Angel Broking

Lakshmi Vilas Bank - Angel Broking

WIPRO Buyback record date announcement - Angel Broking

TCS buyback record date announcement - Angel Broking

Banks Sector Update - Collection efficiency - a positive surprise! - HDFC Securities

Quant Pick - Max Financial Services - ICICI Direct

Graphite India - Q2FY21 Result Update - ICICI Direct

Gladiator Stocks - Maruti Suzuki India - ICICI Direct

Exide Industries - Q2FY21 Result Update - ICICI Direct

Mishra Dhatu Nigam - Execution outlook remains strong - ICICI Securities

Bharat Electronics - Diversifying into multiple revenue streams - ICICI Securities

Wipro Ltd - Virtual Analyst Meet Update - ICICI Direct

Avadh Sugar & Energy - November 2020 - Company Update - ICICI Direct

Mahindra Lifespace Developers - H1FY21 Company Update - ICICI Direct

Quant Pick - Godrej Consumer Products - ICICI Direct



Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019